PARP inhibitors for cancer therapy /
PARP Inhibitors for Cancer Therapy provides a comprehensive overview of the role of PARP-poly ADP ribose polymerase-in cancer therapy. The volume covers the history of the discovery of PARP and its role in DNA repair. Additionally, it describes the discovery of the PARP family, and includes a discus...
Saved in:
| Corporate Author: | |
|---|---|
| Other Authors: | , |
| Format: | eBook |
| Language: | English |
| Published: |
Cham
Springer International Publishing Imprint: Humana Press
2015.
|
| Series: | Cancer Drug Discovery and Development,
83 |
| Subjects: | |
| Online Access: | Click here to view the full text content |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Table of Contents:
- History of the discovery of poly (ADP-ribose)
- Discovery of the PARP superfamily and focus on the lesser exhibited but not lesser talented members
- The role of PARPs in DNA Strand Break Repair
- TIPs: Tankyrase Interacting Proteins
- PARP and Carcinogenesis
- Multitasking roles for poly(ADP-ribosyl)ation in aging and longevity
- Overview of PARP Inhibitor Design and Optimization
- Structure Based Design of PARP Inhibitors
- Preclinical chemosensitization by PARP inhibitors
- Classification of PARP inhibitors based on PARP trapping and catalytic inhibition, and rationale for combinations with topoisomerase I inhibitors and alkylating agents
- Radiosensitisation by poly(ADP-ribose) polymerase inhibition
- The vasoactivity of PARP inhibitors
- Synthetic lethality with Homologous Recombination Repair defects
- Targeting tumour hypoxia with PARP Inhibitors: Contextual synthetic lethality
- Other determinants of sensitivity
- Synthetic sickness with molecularly targeted agents against the EGFR pathway
- Disruption of DNA repair by cell cycle and transcriptional CDK inhibition
- Resistance to PARP Inhibitors Mediated by Secondary BRCA1/2 Mutations
- PARP inhibitor resistance - what is beyond BRCA1 or BRCA2 restoration
- Introduction to PARPi clinical trials and future directions
- Clinical trials investigating PARP inhibitors as single agents
- Clinical trials of PARP inhibitors with chemotherapy
- Combination of PARP inhibitors with clinical radiotherapy
- Biomarkers for PARP Inhibitors.